Morten Sogaard, Head at Pfizer to Speak at 8th Modern Drug Summit Oct 24-26, 2012

Monrovia, California (PressExposure) September 23, 2012 -- Morten Sogaard, Executive Director and Head of Biotechnology and Precision Medicine External R&D Innovation at Pfizer will give a plenary keynote presentation on "Partnering to Deliver the Promise of Precision Medicine" at the 8th Modern Drug Discovery & Development Summit taking place on October 24-26, 2012 in Philadelphia, PA

Health care and Pharmaceutical R&D today is expensive, reactive and often ineffective - largely because we don't understand the diseases and patients we are treating as well as we would like to. We need to more precisely measure patient disease phenotypes and correlate it with molecular markers to better understand disease and effect of drug treatment. Pfizer has term the application of this approach of integrating clinical and molecular information to drug discovery Precision Medicine R&D. In his talk, Dr. Sogaard will give examples of how Precision Medicine and diagnostics are applied in Pfizer R&D projects. Particular emphasis will be put on innovative partnerships and why a open R&D Ecosystem will be essential to the success of Precision Medicine.

Benefits of his presentation include:
Overview of Precision Medicine R&D concept
Examples of Application of Precision Medicine R&D in Pfizer Projects
Examples of Pfizer Precision Medicine R&D partnerships
Overview of how genetics and omics will contribute to success of PreM R&D

Dr. Morten received his Ph.D. in biochemistry from the University of Copenhagen. Following post-doctoral studies at Sloan-Kettering Institute in New York, he moved to Pharmacia in Sweden, where he was section head and project leader for oncology antibody therapeutics. In 1998, he moved to AstraZeneca, Sweden as head of the Molecular Sciences Department and became responsible for genomics, genetics and protein family research and head of AZ's global nuclear receptor program. In 2004 Morten moved to Boehringer Ingelheim in Ridgefield, CT as VP and global head of enabling technology and a member of BI's global research leadership team. In this role he helped build a world-wide enabling technology function comprising global technology skill centers, research informatics and an infrastructure for biologics research. Morten has been with Pfizer since 2009. Dr. Morten's team is responsible for technology and oncology collaborations.

GTC's 8th Modern Drug Discovery and Development Summit features a plenary keynote session followed by five parallel tracks:
9th Stem Cell Research and Therapeutics Conference
7th Assay and Drug Discovery Technologies Conference
4th Translational Medicine Conference
3rd Pharmacokinetics and Pharmacodynamics Conference
Biotechnology Transfer and Commercialization Conference

For more information, please visit

About GTC Conferences

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source:

Press Release Submitted On: September 23, 2012 at 10:03 pm
This article has been viewed 99498 time(s).